For the best quality audio, we encourage you to use your computer’s audio.

If you cannot join through digital audio, you may join by phone in listen-only mode:
+1 408 638 0968 or +1 646 558 8656
Passcode: 115 393 676

All questions for the Q&A portion must be submitted through the webinar system. Please select the Q&A button at the bottom of the webinar and enter questions there.
Potential for Falsely Low Blood Lead Test Results from LeadCare® Analyzers

Clinician Outreach and Communication Activity (COCA) Webinar
May 24, 2017
Accreditation Statements

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians. The Centers for Disease Control and Prevention designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation. This activity provides 1.0 contact hour.

IACET CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 1.0 CEU’s for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designed for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.

CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is a designated event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is 0387-0000-17-156-L04-P and enduring 0387-0000-17-156-H04-P course category. Course Category: This activity has been designated as knowledge-based. Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.

AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education in the jurisdictions which recognize AAVSB RACE approval. Please contact the AAVSB RACE Program at race@aavsb.org if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.

CPH: The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credit for this program.
Continuing Education Disclaimer

CDC, our planners, presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.

Planners have reviewed content to ensure there is no bias.
TODAY’S PRESENTER

Adrienne Ettinger ScD, MPH, MS
Medical Officer
Chief, Healthy Homes and Lead Poisoning Prevention Program
National Center for Environmental Health
Centers for Disease Control and Prevention
Robert Jones, PhD
Chief, Inorganic and Radiation Analytical Toxicology Branch
National Center for Environmental Health
Centers for Disease Control and Prevention
Potential for Falsely Low Blood Lead Test Results from LeadCare® Analyzers

Adrienne S. Ettinger, ScD, MPH, MS
Chief, Healthy Homes and Lead Poisoning Prevention Program

Robert Jones, PhD
Chief, Inorganic and Radiation Analytical Toxicology Branch
Objectives

At the conclusion of the session, the participant will be able to:

1. Describe the importance of lead testing among children and pregnant or lactating women.
2. List the patients who are most at risk for falsely low blood lead level test results.
3. Determine which of their patients need to be retested.
4. Understand and discuss the safety alert and need for retesting with their patients.
Target Audience

• Health care professionals who perform blood lead tests using Magellan Diagnostic’s LeadCare® Testing Systems

• Laboratories that use Magellan’s LeadCare® Testing Systems as part of diagnostic applications

• Laboratory personnel who interpret the results of Magellan’s LeadCare® Testing Systems
FDA Safety Communication

- On May 17, 2017, the U.S. FDA issued a safety communication that involved a Class I recall for LeadCare® (all versions). Available at: https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm558733.htm
- FDA is warning that Magellan Diagnostics’ LeadCare® Testing Systems should no longer be used with venous blood samples due to the potential for falsely low test results
- FDA is aggressively investigating the root cause of the problem
- Not all blood lead tests are affected
Potential Public Health Risk

- CDC was contacted by FDA requesting assistance in assessing the potential public health risk of a negative bias associated with Magellan’s LeadCare® Testing Systems that could underestimate blood lead test results.
- This safety alert applies to venous blood lead tests conducted using Magellan Diagnostics’ LeadCare® analyzers whether the patient is a child or an adult.
- However, children (and pregnant and breastfeeding women) are particularly vulnerable to lead exposure due to the effect on children’s developing brains and organ systems.
Lead Exposure

- Lead exposure can affect nearly every system in the body. Because low level exposure often occurs with no obvious symptoms, it frequently goes unrecognized.
- A blood lead test is the best way to identify lead exposure.
  - No safe blood lead level has been identified.
- Approximately half a million U.S. children ages 1-5 years have blood lead levels above 5 micrograms per deciliter (µg/dL), the reference level at which CDC recommends public health actions be initiated.
Blood Lead Testing

The three main methods to measure blood lead are:

ICP-MS – Inductively coupled plasma mass spectrometry (ICP-MS)

GFAAS – Graphite furnace atomic absorption spectroscopy (GFAAS)

Leadcare® – Point-of-care (POC) and Laboratory-based Anodic Stripping Voltammetry (ASV)

• All blood lead measurements must be CLIA Compliant (waived or not-waived)

• Non-waived testing laboratories must participate in a CLIA approved Proficiency Testing (PT) Program; many waived facilities also participate

• Current CLIA performance criteria is ±4 µg/dL or 10% which ever is greater
Magellan Diagnostics’ LeadCare® Products

Point-of-care Analyzer (FDA 510(k) cleared device, CLIA waived)

FDA 510(k) cleared devices for quantification of lead in whole blood in a moderately or highly complex CLIA compliant laboratory
Recommendations for Re-testing

CDC recommends that healthcare providers re-test patients who:

1) are **younger than 6 years (72 months) of age** at the time of the alert (May 17, 2017) and

2) had a **venous blood lead test** result of **less than 10 micrograms per deciliter (µg/dL)** analyzed using a Magellan Diagnostics’ LeadCare® Testing System at an onsite (e.g., healthcare facility) or at an offsite laboratory.

CDC also recommends that healthcare providers re-test **currently pregnant or lactating women** who had a **venous blood lead test** performed using a Magellan Diagnostics’ LeadCare® Testing System.
Flow Diagram for Determining Potentially Affected Blood Lead Tests and the Need for Re-testing

START

Is test capillary or venous?

- Capillary: NOT AFFECTED BY THIS ALERT
- Venous: Laboratory analyzer used?
  - Analyzer other than LeadCare®: NOT AFFECTED BY THIS ALERT
  - LeadCare®: Potential for falsely low results

- Unsuspected

- Is child <72 months of age?
  - Yes: Is blood lead level <10 µg/dL?
    - Yes: RETEST
    - No: Is currently a pregnant or lactating woman?
      - Yes: RETEST
      - No: NOT AFFECTED BY THIS ALERT

- Unsuspected
Future Blood Lead Testing

• Send venous samples to Clinical Laboratory Improvement Amendments (CLIA)-compliant laboratories using inductively coupled plasma mass spectrometry (ICP-MS) or graphite furnace atomic absorption spectrometry (GFAAS) (also known as electrothermal atomic absorption spectrometry [ETAAS]) instruments

• Send capillary samples to CLIA-compliant laboratories using any CLIA compliant analyzer including ICP-MS, GFAAS, or LeadCare® Testing Systems
Follow-up of Re-testing Results

• If re-testing indicates blood lead levels in excess of the CDC reference level (www.cdc.gov/nceh/lead/acclpp/blood_lead_levels.htm), or the state or local action level, the healthcare provider or public health official should refer to CDC and/or local guidelines for appropriate follow-up action (www.cdc.gov/nceh/lead/acclpp/actions_blls.html)

• Re-tests are not recommended if the provider is certain that analyzers other than those described by this Health Advisory were used to analyze the venous blood samples
Summary

• The U.S. Food and Drug Administration (FDA) has issued a safety communication warning advising that Magellan Diagnostics’ LeadCare® analyzers (LeadCare, LeadCare II, LeadCare Ultra and LeadCare Plus) should no longer be used with venous blood samples because they might result in falsely low test results.

• The FDA safety alert does not apply to capillary blood lead test results collected by fingerstick or heelstick.

• CDC is recommending re-testing of potentially affected tests for certain groups of children and pregnant or breastfeeding women.

• For future blood lead testing, venous samples should be analyzed only by CLIA-compliant laboratories using ICP-MS, GFAAS, or ETAAS.
Next Steps

• CDC is working with public health officials throughout the United States to determine where the analyzers were used and which blood lead test results might be affected

• FDA is leading the investigation to determine the root cause of the LeadCare® issue. CDC is in communication with FDA on the issue.
References

Available at: https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm558733.htm

CDC Health Alert Network. Potential for Falsely Low Blood Lead Test Results from LeadCare® Analyzers, May 17, 2017.
Available at: https://emergency.cdc.gov/han/han00403.asp
For More Information

CDC’s Lead Poisoning Prevention Program: https://www.cdc.gov/nceh/lead/

CDC’s Lead and Multi-element Proficiency Program: https://www.cdc.gov/labstandards/lamp.html
To Ask a Question

- **Using the Webinar System**
  - Click the Q&A button in the webinar
  - Type your question in the Q&A box
  - Submit your question
Thank you for joining!

Centers for Disease Control and Prevention
Atlanta, Georgia
http://emergency.cdc.gov/coca
Today’s webinar will be archived

**When:** A few days after the live call

**What:** All call recordings (audio, webinar, and transcript)

**Where:** On the COCA Call webpage

https://emergency.cdc.gov/coca/calls/2017/callinfo_052417.asp
Continuing Education for COCA Calls

All continuing education (CME, CNE, CEU, CECH, ACPE, CPH, and AAVSB/RACE) for COCA Calls are issued online through the CDC Training & Continuing Education Online system (http://www.cdc.gov/TCEOnline/).

Those who participated in today’s COCA Call and who wish to receive continuing education should complete the online evaluation by June 3, 2017 with the course code WC2286. Those who will participate in the on demand activity and wish to receive continuing education should complete the online evaluation between June 3, 2017 and May 4, 2019 will use course code WD2286.

Continuing education certificates can be printed immediately upon completion of your online evaluation. A cumulative transcript of all CDC/ATSDR CE’s obtained through the CDC Training & Continuing Education Online System will be maintained for each user.
Join the COCA Mailing List

Receive information about:
• Upcoming COCA Calls
• Health Alert Network notices
• CDC public health activations
• Emerging health threats
• Emergency preparedness and response conferences and training opportunities

http://emergency.cdc.gov/coca